The Promise of P.L.E.A.S.E.®- Explanation by Christof Boehler, CEO of Pantec Biosolutions




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The Promise of P.L.E.A.S.E.®- Explanation by Christof Boehler, CEO of Pantec Biosolutions
Released on: October 17, 2011. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Christof Boehler, CEO of Pantec Biosolutions AG.
Business model
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston, in September 2011. On this show I have Christof Boehler, who is CEO of a company called Pantec BioSolutions based in Liechtenstein, in Europe. Welcome to the show.
Christof Boehler:
Thank you for having me.
Fintan Walton:
Thank you Christof Boehler for coming on the show, because I want to learn a little bit more about your company, how would you describe Pantec BioSolutions as a company? What sort of company is it?
Christof Boehler:
Well Pantec BioSolutions is a biomedical company, it's all about drug delivery, we have developed a microporation technology a laser based microporation technology that allows macromolecules travel and permeate across the skin and to be made available systemically.
Fintan Walton:
Okay, so with Pantec BioSolutions what is your actual business model?
Christof Boehler:
Our business model is twofold we have the P.L.E.A.S.E. professional device which comes out of our P.L.E.A.S.E. platform which we starting to sell in Europe as we speak, it will be sold to dermatologists together with distributors and we were actually looking seeking collaboration for global distribution agreements. The second line of products will be clinical candidates that will be used in combination with the P.L.E.A.S.E. platform for drug delivery applications and these programs will be combined with our partners with pharmaceutical partners that are also going to fund the project.
Fintan Walton:
Okay. So that particular device is specifically for clinical use?
Christof Boehler:
Correct, We will be launching this product to professionals initially.
Fintan Walton:
Okay, so that would be your first revenue stream coming into your company?
Christof Boehler:
Absolutely, we are actually launching the product today in Europe.
Fintan Walton:
Okay, good luck with that.
Christof Boehler:
Thank you.
Fintan Walton:
And so then what is the other part of the business model?
Christof Boehler:
In the future as I said we will we are launching today the P.L.E.A.S.E. professional product this is a benchtop device in the future we will he having a handheld version of it which goes into for example medical spas, but also can be used by patients at home to deliver drugs such as hormone for infertility treatment to avoid needles. Speaking of infertility treatment we have two clinical candidates that we have in clinical Phase I\II we have shown proof of concept for delivery of follicle stimulating hormone coming through a patch, so it's the first delivery of a macromolecule across the skin showing follicle growth as well as a pregnancy so we've achieved a pregnancy which is very great.
Fintan Walton:
Okay, and why is it important to deliver using your device, what's the advantage?
Christof Boehler:
Having the device is absolutely important you cannot deliver macromolecules such as proteins and antibodies without such a device you need very precise microporation technology that allows those molecules to permeate.
Fintan Walton:
Right, so that would be a substitute to using just than using as an injectable?
Christof Boehler:
Absolutely.
Collaboration strategy
Fintan Walton:
Right. So in that pursuit in the pursuit of identifying specific drugs that can be used for specific treatments do you also look for collaborations with other pharmaceutical companies is that one of your aims?
Christof Boehler:
Yes it is, we have already a couple of collaborations, we have one collaboration in the infertility space we work with a reputable pharma company and that gives us the FSH molecule to do further studies with it. We have a collaboration in actually in the wider Boston area were we deliver interference RNA into the skin and that's also a dermatology target application. So this is going quite well, we showed active RNA in not only we can deliver the molecule, but also it enters the cells further down into skin.
Uniqueness of YAG laser technology
Fintan Walton:
Okay. Just going back to the technology underlying technology what is the uniqueness of your technology that differentiates you from other companies doing similar things?
Christof Boehler:
The technology is true unique it is so called diode-pumped laser erbium YAG laser technology it combines existing erbium YAG lasers that are out there in the market for longer time with the benefits of a CO2 laser, what I am saying is you have the smoothness of the erbium YAG laser but also the depth penetration of energy of a CO2 laser so it's truly a novel device creating those very precise micropores, we can gradually grill those holes if you will so for the patient it is actually painless it is very easy to use also, it hasn't been seen in the market and we had to really develop it to deliver those drugs so precisely and also reliably.
Fintan Walton:
So you would describe it as a breakthrough technology?
Christof Boehler:
Absolutely.
Fintan Walton:
Okay, so obviously companies you are an innovative company presumably collecting a lots of intellectual property IP and so forth. What sorts of company, what sort of organizations are backing you? Who are your investors? What type of investors do you have in your organization?
Christof Boehler:
Well we have a five strong founders and I am one of them, it's a bunch of interdisciplinary entrepreneurs if you will a medical doctor infertility treatment, two engineers in high-end electronics, pharmacist myself with a chemistry commercial background. We are backed, I mean this is the founders and we are backed by family offices and one venture capital Company.
Fintan Walton:
Okay. And presumably you are private, you are privately held company at this stage?
Christof Boehler:
Yes, it's a private company.
Future plans
Fintan Walton:
Right, So today as you've said you are launching your first product this device in Europe, what is your strategy then for going forward? What do we what can we expect from Pantec BioSolutions over the next few years? What key things are gonna happen?
Christof Boehler:
Well the key things is as mentioned is the launch of the P.L.E.A.S.E. professional benchtop product into the dermatology space first aesthetic, but also medical dermatology when we look at white skin cancer novel therapies for white skin cancer we have actually clinical studies investigated driven studies that tell us that we could reduce time to therapy by weeks to be continued. We also gonna have a handheld device which comes out as the same platform which will be used in aesthetic dermatology as well as to help deliver drugs at home by the patient. And the third thing is really we gonna have more collaborations when we help solving delivery problems, drug delivery problems of our pharma customers and the partners.
Fintan Walton:
Christof, thank you very much indeed for coming on the show.
Christof Boehler:
Thank you very much.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Christof Boehler
CEO
Christof Boehler is currently CEO of Pantec BioSolutions AG. After finishing his PhD in chemistry at ETH Zurich dealing with bio-polymeric drug release systems, Christof moved to the United States for a Postdoc at the Salk and Scripps Research Institutes in La Jolla (CA, USA) carrying out bio-medical basic research. From there he started to work as the head of development for a start up Biotech Company in Zurich, whose process has now been commercialized. Realizing the need to develop his commercial know-how, he moved into product management of research chemicals and biologicals at Fluka Chemie AG (a Sigma Aldrich company, Buchs, CH). During his Fluka time he completed a postgraduate executive degree in "International Management" at the FH Liechtenstein and UBC Vancouver (Canada). His further career involved Business Development Manager Europe and Business Manager for Maybridge, a Drug Discovery service company, and finally Marketing Director "Drug Discovery Chemicals" for Acros/Maybridge (Fisher Scientific). Christof brings into the company excellent knowledge in the bio-medical sector, proven hands on commercial skills, as well as a global network of key decision makers in the pharmaceutical and biotech industries
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Pantec BioSolutions AG
Pantec BioSolutions AG positions itself as a demand driven drug delivery solution provider. The company's primary customers are Pharmaceutical firms that wish to in-license novel technologies such as the P.L.E.A.S.E. platform in order to manage their product life cycles through new formulations and delivery strategies that give them new marketing advantage over their competition.